thalidomide has been researched along with Bone Loss, Osteoclastic in 8 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Osteonecrosis of the jaw (ONJ) is an emerging serious side effect of the new generation bisphosphonates with a growing number of reports related to this pathological entity." | 7.75 | Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid. ( Aki, SZ; Cetiner, M; Cetiner, S; Gultekin, SE; Haznedar, R; Kahraman, SA; Kocakahyaoglu, B; Sucak, GT, 2009) |
| "Osteolytic bone disease in multiple myeloma (MM) is caused by enhanced osteoclast (OCL) activation and inhibition of osteoblast function." | 6.73 | Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. ( Anderson, KC; Breitkreutz, I; Chauhan, D; Hideshima, T; Mitsiades, C; Munshi, NC; Okawa, Y; Raab, MS; Raje, N; Richardson, PG; Vallet, S, 2008) |
| "In the present study, markers of bone resorption [urinary free pyridinoline (PYD), deoxypyridinoline (DPYD), N-terminal telopeptide of collagen I (NTX) and C-terminal telopeptide (serum crosslaps)] and of bone formation [bone alkaline phosphatase (BAP) and osteocalcin] were evaluated at diagnosis and after induction therapy in 40 patients (23M, 17F, median age = 53." | 6.72 | First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma. ( Baccarani, M; Boni, P; Cangini, D; Cavo, M; Ceccolini, M; Cellini, C; Parente, R; Perrone, G; Tacchetti, P; Tosi, P; Tura, S; Zamagni, E, 2006) |
| "We conclude that RD reduces bone resorption only in responding patients with relapsed/refractory myeloma but has no effect on bone formation." | 5.40 | The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: final results on 205 patients of the Greek myeloma study group. ( Christoulas, D; Dimopoulos, MA; Gavriatopoulou, M; Gkotzamanidou, M; Kastritis, E; Katodritou, E; Koulieris, E; Kyrtsonis, MC; Michalis, E; Papanikolaou, X; Papatheodorou, A; Pouli, A; Terpos, E; Zervas, K, 2014) |
| "To explore the difference of effects of two regimens (bortezomib and dexamethasone, BD; and thalidomide and dexamethasone, TD) on bone disease in multiple myeloma (MM)." | 3.77 | [Effect of different regimens on bone disease of multiple myeloma]. ( Bao, L; Huang, XJ; Lai, YY; Lu, J; Lu, XJ; Zhang, XH; Zhu, HH, 2011) |
| " Osteonecrosis of the jaw (ONJ) is an emerging serious side effect of the new generation bisphosphonates with a growing number of reports related to this pathological entity." | 3.75 | Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid. ( Aki, SZ; Cetiner, M; Cetiner, S; Gultekin, SE; Haznedar, R; Kahraman, SA; Kocakahyaoglu, B; Sucak, GT, 2009) |
| "CC-4047, an immunomodulatory analog of thalidomide, inhibits multiple myeloma with unknown effects on the human osteoclast lineage." | 3.73 | Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. ( Anderson, G; Anderson, J; Donnenberg, A; Donnenberg, V; Ghobrial, I; Gries, M; Honjo, T; Kurihara, N; Lentzsch, S; Mapara, MY; Roodman, D; Stirling, D, 2006) |
| "Osteolytic bone disease in multiple myeloma (MM) is caused by enhanced osteoclast (OCL) activation and inhibition of osteoblast function." | 2.73 | Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. ( Anderson, KC; Breitkreutz, I; Chauhan, D; Hideshima, T; Mitsiades, C; Munshi, NC; Okawa, Y; Raab, MS; Raje, N; Richardson, PG; Vallet, S, 2008) |
| "In the present study, markers of bone resorption [urinary free pyridinoline (PYD), deoxypyridinoline (DPYD), N-terminal telopeptide of collagen I (NTX) and C-terminal telopeptide (serum crosslaps)] and of bone formation [bone alkaline phosphatase (BAP) and osteocalcin] were evaluated at diagnosis and after induction therapy in 40 patients (23M, 17F, median age = 53." | 2.72 | First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma. ( Baccarani, M; Boni, P; Cangini, D; Cavo, M; Ceccolini, M; Cellini, C; Parente, R; Perrone, G; Tacchetti, P; Tosi, P; Tura, S; Zamagni, E, 2006) |
| "Novel therapies for multiple myeloma (MM) can target mechanism(s) in the host-MM bone marrow (BM) microenvironment mediating MM progression and chemoresistance." | 1.46 | A novel agent SL-401 induces anti-myeloma activity by targeting plasmacytoid dendritic cells, osteoclastogenesis and cancer stem-like cells. ( Anderson, KC; Brooks, CL; Chauhan, D; Das, DS; Macri, V; Ray, A; Richardson, P; Song, Y, 2017) |
| "We conclude that RD reduces bone resorption only in responding patients with relapsed/refractory myeloma but has no effect on bone formation." | 1.40 | The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: final results on 205 patients of the Greek myeloma study group. ( Christoulas, D; Dimopoulos, MA; Gavriatopoulou, M; Gkotzamanidou, M; Kastritis, E; Katodritou, E; Koulieris, E; Kyrtsonis, MC; Michalis, E; Papanikolaou, X; Papatheodorou, A; Pouli, A; Terpos, E; Zervas, K, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ray, A | 1 |
| Das, DS | 1 |
| Song, Y | 1 |
| Macri, V | 1 |
| Richardson, P | 1 |
| Brooks, CL | 1 |
| Chauhan, D | 2 |
| Anderson, KC | 2 |
| Terpos, E | 2 |
| Christoulas, D | 2 |
| Kastritis, E | 2 |
| Katodritou, E | 1 |
| Papatheodorou, A | 1 |
| Pouli, A | 1 |
| Kyrtsonis, MC | 1 |
| Michalis, E | 1 |
| Papanikolaou, X | 1 |
| Gkotzamanidou, M | 2 |
| Koulieris, E | 1 |
| Gavriatopoulou, M | 2 |
| Zervas, K | 1 |
| Dimopoulos, MA | 2 |
| Roussou, M | 1 |
| Migkou, M | 1 |
| Eleutherakis-Papaiakovou, E | 1 |
| Kanellias, N | 1 |
| Manios, E | 1 |
| Papadimitriou, C | 1 |
| Breitkreutz, I | 1 |
| Raab, MS | 1 |
| Vallet, S | 1 |
| Hideshima, T | 1 |
| Raje, N | 1 |
| Mitsiades, C | 1 |
| Okawa, Y | 1 |
| Munshi, NC | 1 |
| Richardson, PG | 1 |
| Cetiner, S | 1 |
| Sucak, GT | 1 |
| Kahraman, SA | 1 |
| Aki, SZ | 1 |
| Kocakahyaoglu, B | 1 |
| Gultekin, SE | 1 |
| Cetiner, M | 1 |
| Haznedar, R | 1 |
| Bao, L | 1 |
| Lu, XJ | 1 |
| Zhang, XH | 1 |
| Lai, YY | 1 |
| Zhu, HH | 1 |
| Lu, J | 1 |
| Huang, XJ | 1 |
| Anderson, G | 1 |
| Gries, M | 1 |
| Kurihara, N | 1 |
| Honjo, T | 1 |
| Anderson, J | 1 |
| Donnenberg, V | 1 |
| Donnenberg, A | 1 |
| Ghobrial, I | 1 |
| Mapara, MY | 1 |
| Stirling, D | 1 |
| Roodman, D | 1 |
| Lentzsch, S | 1 |
| Tosi, P | 1 |
| Zamagni, E | 1 |
| Cellini, C | 1 |
| Parente, R | 1 |
| Cangini, D | 1 |
| Tacchetti, P | 1 |
| Perrone, G | 1 |
| Ceccolini, M | 1 |
| Boni, P | 1 |
| Tura, S | 1 |
| Baccarani, M | 1 |
| Cavo, M | 1 |
2 trials available for thalidomide and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma.
Topics: Antineoplastic Agents; B-Cell Activating Factor; Bone Remodeling; Bone Resorption; Boronic Acids; Bo | 2008 |
First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma.
Topics: Adult; Aged; Alkaline Phosphatase; Amino Acids; Antineoplastic Combined Chemotherapy Protocols; Biom | 2006 |
6 other studies available for thalidomide and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
A novel agent SL-401 induces anti-myeloma activity by targeting plasmacytoid dendritic cells, osteoclastogenesis and cancer stem-like cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Resorption; Cell Line, Tumor; Cell Proliferation; Ce | 2017 |
The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: final results on 205 patients of the Greek myeloma study group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone Rem | 2014 |
VTD consolidation, without bisphosphonates, reduces bone resorption and is associated with a very low incidence of skeletal-related events in myeloma patients post ASCT.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Remodeling; Bone Resorption; Boron | 2014 |
Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid.
Topics: Adult; Aged; Bone Density Conservation Agents; Bone Resorption; Dexamethasone; Diphosphonates; Femal | 2009 |
[Effect of different regimens on bone disease of multiple myeloma].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Resorption; | 2011 |
Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1.
Topics: Angiogenesis Inhibitors; Bone Resorption; Cell Differentiation; Cells, Cultured; Dose-Response Relat | 2006 |